Abstract:Cancer immunotherapies have been widely hailed as a breakthrough for cancer treatment in the last decade, epitomized by the unprecedented results observed with checkpoint blockade. Even so, only a minority of patients currently achieve durable remissions. In general, responsive patients appear to have either a high number of tumor neoantigens, a preexisting immune cell infiltrate in the tumor microenvironment, or an 'immune-active' transcriptional profile, determined in part by the presence of a type I interferon gene signature. These observations suggest that the therapeutic efficacy of immunotherapy can be enhanced through strategies that release tumor neoantigens and/or produce a pro-inflammatory tumor microenvironment. In principle, exogenous tumor-targeting bacteria offer a unique solution for improving responsiveness to immunotherapy. This review discusses how tumor-selective bacterial infection can modulate the immunological microenvironment of the tumor and the potential for combination with cancer immunotherapy strategies to further increase therapeutic efficacy. In addition, we provide a perspective on the clinical translation of replicating bacterial therapies, with a focus on the challenges that must be resolved to ensure a successful outcome.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: how to enhance the effectiveness of cancer immunotherapy by using tumor - targeting bacteria as immunostimulants. Specifically, the paper explores the following aspects: 1. **Limitations of cancer immunotherapy**: - Although cancer immunotherapy (such as checkpoint blockade) has made significant progress in the past decade, only a small number of patients can achieve durable remission. - Patients who respond well usually have a high number of tumor neo - antigens, pre - existing immune cell infiltration in the tumor microenvironment, or an "immune - active" transcriptional profile. 2. **Strategies to improve the effectiveness of immunotherapy**: - In order to improve the effectiveness of immunotherapy, strategies that can release tumor neo - antigens and/or create a pro - inflammatory tumor microenvironment need to be developed. - The paper proposes that exogenous tumor - targeting bacteria may provide a unique solution to improve the responsiveness to immunotherapy. 3. **Selective colonization of bacteria in tumors and its mechanisms**: - Bacteria can preferentially accumulate and proliferate in solid tumors through multiple mechanisms, including taking advantage of the unique characteristics of the tumor microenvironment (such as immunosuppression, hypoxia, necrosis, and metabolite enrichment or deficiency). - For example, certain bacterial species (such as Clostridium species) can germinate in tumor necrosis areas, while other bacteria (such as Salmonella and E. coli) can accumulate in hypoxic and necrotic areas. 4. **Regulation of the tumor immune microenvironment by bacteria**: - Selective bacterial infection of tumors can overcome the immunosuppressive tumor microenvironment by inducing immune cell death, stimulating the innate immune response (adjuvant effect), and recruiting cytotoxic immune cells to the tumor microenvironment. - Bacteria can also regulate the immune response or induce immunogenicity by expressing tumor - associated antigens. 5. **Oncolytic effect of bacteria and immunogenic cell death**: - Certain bacteria (such as Salmonella and Listeria) can directly kill tumor cells, resulting in immunogenic cell death (ICD), thereby triggering a strong anti - tumor immune response. - ICD activates the innate and adaptive immune responses by exposing, actively secreting, or passively releasing various damage - related molecular patterns (DAMPs). 6. **Removal of immunosuppressive cell types in the tumor microenvironment**: - Bacteria can reduce the number and function of immunosuppressive cells (such as MDSCs and Tregs) in the tumor microenvironment, thereby alleviating immunosuppression and enhancing the anti - tumor immune response. In summary, this paper aims to explore how to use tumor - targeting bacteria as immunostimulants to improve the effectiveness of cancer immunotherapy by changing the tumor microenvironment and enhancing the immune response.

Tumor-targeting bacteria as immune stimulants – the future of cancer immunotherapy?

Harnessing Bacterial Agents to Modulate the Tumor Microenvironment and Enhance Cancer Immunotherapy

Current Status and Future Directions of Bacteria-Based Immunotherapy

Bacteria-based immunotherapy: A promising frontier in cancer treatment

Exploiting bacteria for cancer immunotherapy

Tweak to Treat: Reprograming Bacteria for Cancer Treatment

Path to bacteriotherapy: From bacterial engineering to therapeutic perspectives

Bacterial-based cancer therapy: An emerging toolbox for targeted drug/gene delivery

Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies

Bacterial‐Mediated Tumor Therapy: Old Treatment in a New Context

Microbiota Manipulation as an Emerging Concept in Cancer Therapy

Intratumoral Microbiota as a Target for Advanced Cancer Therapeutics

Engineering bacteria for cancer immunotherapy

Bacteria colonization in tumor microenvironment creates a favorable niche for immunogenic chemotherapy

Precision strategies for cancer treatment by modifying the tumor-related bacteria

Host–microbe cross talk in cancer therapy

Bacterial immunotherapy: is it a weapon in our arsenal in the fight against cancer?

Utilizing Bacteria-Derived Components for Cancer Immunotherapy

Targeting bacterial metabolites in tumor for cancer therapy: An alternative approach for targeting tumor-associated bacteria

Harnessing Bacterial Membrane Components for Tumor Vaccines: Strategies and Perspectives

The role of intratumoral microorganisms in the progression and immunotherapeutic efficacy of head and neck cancer